2021-01-30 4. 城上城行政中心2F 第二會議室
| 時間 | 主題 | 講者 | 座長 | 簡報 | 錄影 |
|---|---|---|---|---|---|
15:20 ~ 15:50 |
The role of PARP inhibitor in the treatment of mCRPC, how to sequence current therapies? |
楊晨洸 |
鍾孝仁, 黃昭淵, 李經家, 王賢祥 |
||
15:50 ~ 16:20 |
DNA damage repair (DDR) related genes testing strategy in prostate cancer, who and when to be tested? |
虞凱傑 |
鍾孝仁, 黃昭淵, 李經家, 王賢祥 |
||
16:20 ~ 16:50 |
Obstacles for molecular testing in prostate cancer in clinical practice |
黃雲慶 |
鍾孝仁, 黃昭淵, 李經家, 王賢祥 |
||
16:50 ~ 17:20 |
Current evidence gap and unmet need for PARP inhibitors in prostate cancer |
黃逸修 |
鍾孝仁, 黃昭淵, 李經家, 王賢祥 |